Segment Information, EBITDA, Reconciling Items (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021		Dec. 31, 2020
Unallocated costs [Abstract]
Impairment Charges And Gain Loss On Sale Of Assets	[1]	$ 16.0	$ 1.0	$ 19.0		$ 2.0
Stock-based compensation		11.0	11.0	32.0		30.0
Restructuring And Other Special Items	[2]	23.0	15.0	31.0		20.0
Payments for (Proceeds from) Businesses and Interest in Affiliates	[3]	0.0	0.0	1.0		0.0
Other income/(expense),net	[4]	(14.0)	8.0
Other (income)/expense, net		(14.0)	8.0	(23.0)	[4]	19.0	[4]
Non Allocated Corporate Costs Net		37.0	26.0	53.0		41.0
Segment Reporting Information Unallocated Expense	[5]	$ 101.0	$ 45.0	$ 157.0		$ 74.0

[1] Impairment charges and gain (loss) on sale of assets during the three and six months ended December 31, 2021 include fixed asset impairment charges associated with a product in our respiratory and specialty platform.

[2] Restructuring and other special items during the three months ended December 31, 2021 include (i) transaction and integration costs primarily associated with the Bettera acquisition and (ii) restructuring costs associated with the closure of the Bolton facility. Restructuring and other special items during the six months ended December 31, 2021 include (i) transaction and integration costs associated with the Delphi, Hepatic, RheinCell, and Bettera acquisitions and (ii) restructuring costs associated with the closure of the Bolton facility.Restructuring and other special items during the three and six months ended December 31, 2020 include (i) transaction costs associated with the sale of the Blow-Fill-Seal Business and (ii) restructuring costs associated with the closure of the Bolton facility. Restructuring and other special items during the six months ended December 31, 2020 also include transaction and integration costs associated with acquisitions of facilities in Italy and Belgium, the disposal of a site in Australia, and other restructuring initiatives across the Company's network of sites.

[3] Gain on sale of subsidiary for the six months ended December 31, 2021 was due to the sale of the Blow-Fill-Seal Business

[4] Refer to Note 8, Other Expense (Income), Net for details of financing charges and foreign currency translation adjustments recorded within other expense (income), net.

[5] Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: